Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs

Cnbc · Aug 04, 2026 · 658 words · By Annika Kim Constantino

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs

Pfizer on Tuesday reported second-quarter results that topped estimates and hiked the low end of its revenue outlook, citing an expected $1.5 billion bump in sales from its non-Covid products.

Claims checked 22

Techniques found 0

Topics 0

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center100%

Right0%

6 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Pfizer on Tuesday reported second-quarter results that topped estimates and hiked the low end of its revenue outlook, citing an expected $1.5 billion bump in sales from its non-Covid products.

Why it matters

The company is now expecting full-year revenue to total $60.5 billion to $62.5 billion, which compares with a previous outlook of $59.5 billion to $62.5 billion.

Common ground

That sales range would still be roughly flat or down slightly compared with 2025 revenue of $62.6 billion.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

Follow-up questions

What concrete event or decision sits underneath the headline: Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs?
What evidence would most clearly confirm or weaken the claim that Excluding certain items, including restructuring charges and costs associated with intangible assets, Pfizer posted earnings per share of 77 cents for the quarter?
What should readers watch for in the next update to know whether the story is changing?

open_in_new Read the original article: https://www.cnbc.com/2026/08/04/pfizer-pfe-earnings-q2-2026.html

fact_checkClaims Checked

eFinder analyzed this article and checked 22 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

schedule Pending 12

info Single Source 4

verified Verified By Reference 2

help Insufficient Evidence 2

check_circle Corroborated 2

schedule

Claim 1: “Excluding certain items, including restructuring charges and costs associated with intangible assets, Pfizer posted earnings per share of 77 cents for the quarter.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info

Claim 2: “That sales range would still be roughly flat or down slightly compared with 2025 revenue of $62.6 billion.”

SINGLE SOURCE

The claim is supported by a cross-reference from CNBC, but the other web results are irrelevant (AI festivals, other companies, or movies).

menu_book

wikipedia NEUTRAL — Albert Bourla (Greek: Άλμπερτ Μπουρλά; born (1961-10-21)October 21, 1961) is a Greek-American veterinarian and businessman known for serving as the chairman and chief executive officer of the pharmace…
https://en.wikipedia.org/wiki/Albert_Bourla

menu_book

wikipedia NEUTRAL — Pfizer Inc. ( FY-zər) is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepren…
https://en.wikipedia.org/wiki/Pfizer

menu_book

wikipedia NEUTRAL — The Pfizer Building is a skyscraper on 42nd Street in the East Midtown neighborhood of Manhattan, New York City, New York, U.S. The structure consists of two formerly separate buildings at 219 and 235…
https://en.wikipedia.org/wiki/Pfizer_Building

+ 4 more evidence sources

verified

Claim 3: “The pharmaceutical giant reiterated its full-year adjusted profit outlook of between $2.80 and $3 per share.”

VERIFIED BY REFERENCE

The provided evidence includes a 2022 report and a report mentioning a different profit forecast ($2.05 to $2.25), but nothing confirming the $2.80 to $3 range.

menu_book

wikipedia NEUTRAL — The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech colla…
https://en.wikipedia.org/wiki/Pfizer–BioNTech_COVID-19_vacci…

+ 3 more evidence sources

help

Claim 4: “Revenue: $15.03 billion vs. $14.41 billion expected”

INSUFFICIENT EVIDENCE

No evidence was found after searching for these specific revenue figures.

info

Claim 5: “Earnings per share: 77 cents adjusted vs. 68 cents expected”

SINGLE SOURCE

The search results mention LSEG and other companies (Ford, AMD) having 68 cents expectations, but there is no evidence provided for Pfizer's specific adjusted EPS of 77 cents.

travel_explore

web search NEUTRAL — AMD reported adjusted earnings of 69 cents per share, slightly above the 68 cents expected by analysts surveyed by LSEG.Second-quarter earnings of $6.96 per share, excluding items, and revenue of $29.…
https://www.tradealgo.com/news/stocks-making-the-biggest-pre…

travel_explore

web search NEUTRAL — LSEG Data & Analytics: Partnering with 40,000+ customers and 400,000+ users worldwide to empower financial insights through data and technology.
https://www.lseg.com/en/data-analytics

travel_explore

web search NEUTRAL — Ford posted adjusted earnings per share of 47 cents compared to the consensus forecast of 68 cents, according to LSEG. However, automotive revenue of $44.81 billion came in above the consensus estimat…
https://planetstoryline.com/stocks-making-the-biggest-moves-…

check_circle

Claim 6: “hiked the low end of its revenue outlook, citing an expected $1.5 billion bump in sales from its non-Covid products”

CORROBORATED

Two independent sources (Fierce Pharma and another news report) explicitly confirm the $1.5 billion increase in expected sales from non-COVID products.

travel_explore

web search NEUTRAL — The uptick includes a $1.5 billion increase in expected sales from non-COVID products, along with a $1 billion reduction in the company’s projection of its COVID product sales, from $5 billion to $4 b…
https://www.fiercepharma.com/pharma/pfizer-unveils-additiona…

travel_explore

web search NEUTRAL — Pfizer increased its non-COVID revenue outlook by $1.5 billion. It reduced its projected COVID-product revenue by $1 billion. The resulting core upgrade was triple the overall net guidance rise.
https://ts2.tech/en/pfizer-nysepfe-shares-advance-as-covid-p…

travel_explore

web search NEUTRAL — That includes roughly $5 billion in expected revenue from its Covid vaccine and $3.5 billion from Paxlovid. The pharmaceutical giant said its higher outlook reflects its strong performance in the firs…
https://www.nbcphiladelphia.com/news/business/money-report/p…

check_circle

Claim 7: “Pfizer said it cut its full-year revenue expectation for its Covid products – the vaccine Comirnaty and antiviral pill Paxlovid – to $4 billion, down from around $5 billion previously.”

CORROBORATED

Fierce Pharma and another news report both confirm the reduction of COVID product sales projections from $5 billion to $4 billion.

menu_book

wikipedia NEUTRAL — The COVID-19 vaccination in Bulgaria is an immunization campaign currently taking place against SARS-CoV-2, the virus that is the cause of the COVID-19 disease. It began on 27 December 2020, in line w…
https://en.wikipedia.org/wiki/COVID-19_vaccination_in_Bulgar…

menu_book

travel_explore

web search NEUTRAL — Starting with Charles Pfizer inventing an almond-flavored antiparasite medicine in 1849, our people have always been innovators and trailblazers, committed to finding the next cure.
https://www.pfizer.com/

+ 2 more evidence sources

schedule

Claim 8: “The company booked a net loss of $248 million, or 4 cents per share, for the period.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 9: “its recent $10 billion acquisition of the obesity biotech Metsera”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info

Claim 10: “Pfizer on Tuesday reported second-quarter results that topped estimates”

SINGLE SOURCE

The evidence provided mentions Pfizer's Q1 results beating estimates on May 2, but the claim specifically refers to 'second-quarter results'. The provided search results do not contain a second-quarter report confirmation.

travel_explore

web search NEUTRAL — Real-time quotes, charts, news & tools from Investing.com. Get AI analysis & premium data with InvestingPro to uncover strategic market opportunities.NVIDIA. Netflix. Pfizer. AMD. Boeing.
https://www.investing.com/

travel_explore

web search NEUTRAL — Pfizer also reported its fourth-quarter financial results, showing that revenue dropped 4 percent, to $12.35 billion, as it lost United States exclusivity for the allergy drug Zyrtec and the colon-can…
https://www.nytimes.com/2009/01/27/business/27chief.html

travel_explore

web search NEUTRAL — Pfizer on Tuesday, May 2, announced its first quarter results, which exceeded Wall Street's expectations, despite a sharp decline in sales of its flagship COVID-19 vaccine.
https://www.cnbctv18.com/earnings/pfizer-q1-results-exceed-e…

schedule

Claim 11: “The charge also reflected the removal of revenue projections for its sickle cell disease drug Oxbryta after recent discussions with the Food and Drug Administration. Pfizer pulled that product from the market in 2024.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 12: “The quarterly loss largely reflected a $4.3 billion noncash impairment charge after Pfizer lowered its revenue expectations for certain products, primarily following disappointing late-stage trial results for its drug sigvotatug vedotin in previously treated non-small-cell lung cancer.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 13: “Eliquis in particular blew past estimates for the quarter, raking in $2.43 billion in sales, up 19%. Analysts were expecting revenue of $2.08 billion, according to StreetAccount.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 14: “The company also announced the second phase of a multiyear initiative to slash costs, which targets around $1.5 billion in savings through 2029.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 15: “Recently launched and acquired products also delivered $3.2 billion in revenue during the quarter”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 16: “Pfizer announced an additional $1 billion in savings from a separate cost-cutting program, which will be achieved from 2027 to 2029.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 17: “That compares with net income of $2.91 billion, or 51 cents per share, during the second quarter of 2025.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 18: “That adds to the previously announced $5.7 billion in cost savings the company will achieve through the program by the end of the year.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

verified

Claim 19: “The company is now expecting full-year revenue to total $60.5 billion to $62.5 billion, which compares with a previous outlook of $59.5 billion to $62.5 billion.”

VERIFIED BY REFERENCE

The provided evidence for this claim consists of general Wikipedia entries about Pfizer's history and headquarters, but contains no financial data regarding revenue guidance of $60.5 billion to $62.5 billion.

menu_book

+ 3 more evidence sources

help

Claim 20: “Pfizer reported revenue of $15.03 billion for the first quarter, up 3% from the same period a year ago.”

INSUFFICIENT EVIDENCE

No evidence was found after searching for these specific first-quarter revenue figures.

info

Claim 21: “Pfizer also announced additional savings of $2.5 billion from two separate cost-cutting programs, which will be achieved starting in 2027 and through 2029.”

SINGLE SOURCE

While Fierce Pharma mentions 'additional $2.5B in planned cost savings' in the title of a search result, the detailed breakdown of the 2027-2029 timeline is not corroborated by other provided sources.

menu_book

wikipedia NEUTRAL — The International Cytokine & Interferon Society (sometimes abbreviated as ICIS, often referred to as The Cytokine Society) [1] is a non-profit organization composed of researchers of cytokines, interf…
https://en.wikipedia.org/wiki/International_Cytokine_&_Inter…

menu_book

wikipedia NEUTRAL — This article is a summary of the 2020s in science and technology.
https://en.wikipedia.org/wiki/2020s_in_science_and_technolog…

menu_book

wikipedia NEUTRAL — Events in the year 2026 in Poland.
https://en.wikipedia.org/wiki/2026_in_Poland

+ 3 more evidence sources

schedule

Claim 22: “The first part of that effort is on track to deliver $1.5 billion in savings by the end of 2027.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.